Jeet Mukherjee, an analyst from BTIG, maintained the Buy rating on Ascentage Pharma Group International Unsponsored ADR. The associated price target is $48.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jeet Mukherjee has given his Buy rating due to a combination of factors, primarily the strength and global potential of Ascentage Pharma’s two lead oncology assets. He highlights olverembatinib, a third-generation BCR-ABL TKI, which is progressing through three late-stage global trials and already demonstrating strong commercial momentum in China, supported by robust efficacy data in heavily pretreated CML patients and a sizable addressable market.
He also emphasizes lisaftoclax, a next-generation BCL-2 inhibitor designed to overcome key limitations of venetoclax, with multiple phase 3 studies underway across CLL, AML and high-risk MDS that could unlock significant value when results read out in 2027. In addition, he notes that the broader early-stage pipeline, together with the economic upside from Takeda’s option on olverembatinib and a favorable DCF-based valuation, suggests that the current share price does not fully capture AAPG’s long-term growth prospects, supporting a Buy recommendation.